ArticleTrials2021

Rationale and design of the multicentric, double-blind, double-placebo, randomized trial APrepitant versus HYdroxyzine in association with cytoreductive treatments for patients with myeloproliferative neoplasia suffering from Persistent Aquagenic Pruritus. Trial acronym: APHYPAP.

C Le Gall-Ianotto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.